Eli Lilly said it has launched new doses of its obesity treatment drug and reduced its prices.

Eli Lilly has cut the price for vials of its weight-loss drug Zepbound sold online and expanded the range of doses in an attempt to stave off stiff competition from compounding pharmacies and rival Novo Nordisk.

Key Takeaways Eli Lilly lowered the price of two dosage levels of its weight-loss drug Zepbound for patients paying out of pocket.The company also launched new 7.5-mg and 10-mg single-use vials, which cost $499 when refilled every 45 days through Eli Lilly's new "Zepbound Self Pay Journey Program.

Eli Lilly is lowering the cost barrier to its weight loss drug Zepbound.  For many consumers, their insurance denies them coverage for weight loss drugs

Eli Lilly said Tuesday that it will offer more doses of its obesity drug Zepbound in vials and lower the prices of the doses it already sells.

Few big pharma stocks have been bigger winners over the last three years than Eli Lilly and Novo Nordisk. Lilly now ranks as the largest drugmaker in the world, with a market cap of $844 billion, after its shares skyrocketed more than 270%. Novo Nordisk stock is up around 75% despite a pullback in recent months.

Eli Lilly announced a price reduction for its weight-loss drug Zepbound's vials by $50 or more, adapting to stiff competition from compounding pharmacies and Novo Nordisk. The FDA has mandated compounders to stop selling copied forms of these drugs following the shortage list updates,

Eli Lilly (LLY) stock in focus as the company expands Zepbound offerings with new vial formats at discounted prices. Read more here.

Eli Lilly said on Tuesday it has begun selling higher doses of its popular weight-loss drug Zepbound in vials in the U.S. at a $150 discount to the cost of the injector pen versions, as it seeks to spur further demand for the medicine.

Eli Lilly now offers higher doses of its weight-loss drug Zepbound in vial form at a discount to the injector pen versions. This move aims to increase demand amid pressure from investors and competition from Novo Nordisk's Wegovy,